These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22343118)

  • 1. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.
    Novalic Z; van der Wal AM; Leonhard WN; Koehl G; Breuning MH; Geissler EK; de Heer E; Peters DJ
    J Am Soc Nephrol; 2012 May; 23(5):842-53. PubMed ID: 22343118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
    Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
    Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.
    Stayner C; Shields J; Slobbe L; Shillingford JM; Weimbs T; Eccles MR
    Nephrology (Carlton); 2012 Nov; 17(8):739-47. PubMed ID: 22725947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.
    Shillingford JM; Piontek KB; Germino GG; Weimbs T
    J Am Soc Nephrol; 2010 Mar; 21(3):489-97. PubMed ID: 20075061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin-encapsulated nanoparticle delivery in polycystic kidney disease mice.
    Yamaguchi S; Sedaka R; Kapadia C; Huang J; Hsu JS; Berryhill TF; Wilson L; Barnes S; Lovelady C; Oduk Y; Williams RM; Jaimes EA; Heller DA; Saigusa T
    Sci Rep; 2024 Jul; 14(1):15140. PubMed ID: 38956234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.
    Ravichandran K; Zafar I; He Z; Doctor RB; Moldovan R; Mullick AE; Edelstein CL
    Hum Mol Genet; 2014 Sep; 23(18):4919-31. PubMed ID: 24847003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
    Shillingford JM; Murcia NS; Larson CH; Low SH; Hedgepeth R; Brown N; Flask CA; Novick AC; Goldfarb DA; Kramer-Zucker A; Walz G; Piontek KB; Germino GG; Weimbs T
    Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5466-71. PubMed ID: 16567633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
    Huber TB; Walz G; Kuehn EW
    Kidney Int; 2011 Mar; 79(5):502-11. PubMed ID: 21085109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
    Canaud G; Knebelmann B; Harris PC; Vrtovsnik F; Correas JM; Pallet N; Heyer CM; Letavernier E; Bienaimé F; Thervet E; Martinez F; Terzi F; Legendre C
    Am J Transplant; 2010 Jul; 10(7):1701-6. PubMed ID: 20642692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR signaling in polycystic kidney disease.
    Ibraghimov-Beskrovnaya O; Natoli TA
    Trends Mol Med; 2011 Nov; 17(11):625-33. PubMed ID: 21775207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mTOR Signaling Can Prevent the Progression of FSGS.
    Zschiedrich S; Bork T; Liang W; Wanner N; Eulenbruch K; Munder S; Hartleben B; Kretz O; Gerber S; Simons M; Viau A; Burtin M; Wei C; Reiser J; Herbach N; Rastaldi MP; Cohen CD; Tharaux PL; Terzi F; Walz G; Gödel M; Huber TB
    J Am Soc Nephrol; 2017 Jul; 28(7):2144-2157. PubMed ID: 28270414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model.
    Zhu P; Sieben CJ; Xu X; Harris PC; Lin X
    Hum Mol Genet; 2017 Jan; 26(1):158-172. PubMed ID: 28007903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate-conjugated rapamycin slows progression of polycystic kidney disease.
    Shillingford JM; Leamon CP; Vlahov IR; Weimbs T
    J Am Soc Nephrol; 2012 Oct; 23(10):1674-81. PubMed ID: 22859856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
    Torres VE; Boletta A; Chapman A; Gattone V; Pei Y; Qian Q; Wallace DP; Weimbs T; Wüthrich RP
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1312-29. PubMed ID: 20498248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
    Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
    Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.